Health Economics›Melanoma›Metastatic or unresectable disease

Metastatic or unresectable disease

Melanoma · 28 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 8 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ipilimumab and Sargramostim Variant #01	—	R 786 153	84d	—	17.5 mo	—	—	—
Ipilimumab monotherapy Variant #01	—	R 471 692	84d	3.1 mo	11.5 mo	2	R 943 384 PFS proxy	5
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	4.9 mo	32.7 mo	11	R 3 156 508 PFS proxy	7
Ipilimumab-Nivolumab Variant #01 Partial	—	R 235 846	21d	—	—	—	—	—
Nivolumab-Ipilimumab Variant #01 Partial	—	R 235 846	21d	—	—	—	—	1
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	~11.5 mo	~72.0 mo	~9	~R 707 538 PFS proxy · indirect	6
nab-Paclitaxel monotherapy Variant #01	—	R 45 710	28d	4.8 mo	—	6	R 274 259 PFS proxy	1
Temozolomide monotherapy Variant #13	—	R 8 153	28d	~1.6 mo	—	~2	~R 16 306 PFS proxy · indirect	1
CDB Variant #01 Partial	—	R 4 002	42d	—	—	—	—	—
Carboplatin and Dacarbazine Variant #01	—	R 3 373	28d	—	—	—	—	—
Dacarbazine and Tamoxifen Variant #01	—	R 3 254	21d	—	11.0 mo	—	—	—
BVD Variant #01 Partial	—	R 3 151	28d	—	—	—	—	—
BCG and Dacarbazine Variant #01	—	R 3 079	21d	—	—	—	—	—
CVD (Vindesine) Variant #01 Partial	—	R 2 298	21d	—	~12.0 mo	—	—	—
Cisplatin, Dacarbazine, Interferon alfa-2b Variant #01	—	R 2 298	28d	—	9.0 mo	—	—	1
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	1.7 mo	9.4 mo	2	R 4 439 PFS proxy	4
Cisplatin, Dacarbazine, Tamoxifen Variant #01	—	R 2 152	21d	—	—	—	—	—
Dacarbazine monotherapy Variant #01	—	R 2 094	21d	1.5 mo	9.6 mo	3	R 6 282 PFS proxy	6
Dacarbazine and Interferon alfa-2a Variant #01	—	R 1 971	21d	—	11.0 mo	—	—	—
BHD Variant #01 Partial	—	R 1 968	28d	—	—	—	—	—
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	~3.2 mo	~9.5 mo	~4	~R 973 PFS proxy · indirect	83
High-dose Interleukin-2 N/A - secondary systemic drug	—	R 43	28d	—	—	—	—	—
CVD, IL-2, IFN alfa-2b - sequential biochemotherapy N/A - secondary systemic drug	—	R 0	21d	—	~118.8 mo	—	—	1
Placebo Partial	—	—	—	—	7.4 mo	—	—	1
Sargramostim monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Nivolumab monotherapy Variant #01 Partial	—	—	14d	~4.6 mo	~34.1 mo	~11	—	10
BCG vaccine monotherapy Variant #01 Partial	—	—	30d	—	38.6 mo	—	—	1
Low-dose Interleukin-2 Variant #01 Partial	—	—	42d	—	—	—	—	—

28 of 28 regimens shown